NCT00594165 - An Open-Label Extension Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Early-Stage Parkinson's Disease. | Biotech Hunter

Enrollment

217

Participants

Timeline

Start Date

June 30, 2002

Primary Completion Date

November 30, 2008

Study Completion Date

November 30, 2008

Conditions

Early-Stage Parkinson's Disease

Interventions

DRUG

Rotigotine

"Rotigotine trans-dermal patches:~10 cm2 (2 mg/24 hours); 20 cm2 (4 mg/24 hours); 30 cm2 (6 mg/24 hours); 40 cm2 (8 mg/24 hours)~Optimal dosing:~During the first year:~The maximum Rotigotine dose allowed is 6 mg/24 hours.~After the first year: allowed dose increase of Rotigotine up to a maximum of 16 mg/24 hours."

Trial Locations (42)

Unknown

Peoria

Phoenix

Tucson

Fountain Valley

Fresno

Los Angeles

Englewood

Danbury

New Haven

Miami

Pompano Beach

Sunrise

Atlanta

Chicago

Fort Wayne

New Orleans

Boston

Southfield

Minneapolis

St Louis

Henderson

New Brunswick

Albany

Louisville

New York

Asheville

Durham

Cleveland

Columbus

Toledo

Upland

Dallas

Houston

San Antonio

Richmond

Roanoke

Milwaukee

Calgary

Edmonton

Vernon

Ottawa

Saskatoon